Nusinersen

Nusinersen (trade name Spinraza®) is a drug used to treat spinal muscular atrophy (SMA). It is an antisense oligonucleotide (ASO) therapeutic designed to increase the production of survival motor neuron (SMN) protein, which is deficient in people with SMA. Nusinersen is administered as an intrathecal injection, and is the first therapeutic approved for all types of SMA. Clinical trials have shown that Nusinersen can improve motor function in infants and children with SMA and can extend survival in some cases.

Nusinersen, also marketed under the brand name Spinraza, is a medication specifically used to treat Spinal Muscular Atrophy (SMA). Here's a breakdown of its key aspects:

Function:

• Nusinersen belongs to a class of drugs called antisense oligonucleotide inhibitors.
• It works by increasing the production of a protein called survival motor neuron (SMN), which is crucial for the function of muscles and nerves.
• In individuals with SMA, a genetic mutation hinders SMN production, leading to muscle weakness and wasting.

Applications:

• Nusinersen is approved to treat all types of SMA, affecting both children and adults.

Administration:

• Nusinersen is administered through intrathecal injection, meaning it's delivered directly into the fluid-filled space surrounding the spinal cord.
• The initial dosage involves a series of injections, followed by regular maintenance doses typically given every four months.

Important Points:

• Nusinersen is a prescription medication and should only be used under the supervision of a qualified healthcare professional.
• While it can improve muscle function and slow down the progression of SMA, it is not a cure.
• Nusinersen can cause side effects like:
  • Increased risk of infections
  • Constipation
  • Scoliosis (curvature of the spine)